Elypta AB

Elypta is developing a liquid biopsy platform based on a scalable laboratory assay and artificial intelligence algorithms trained by our clinical database.

Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in our lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. We also explore several other indications to understand the full potential for Elypta’s platform.